As Pfizer (PFE) Valuation Declined, Shareholder Plancorp Has Decreased by $958,405 Its Holding; Agf Investments Increases Position in Synchrony Financial (SYF)

February 15, 2018 - By Michael Collier

Plancorp Llc decreased its stake in Pfizer Inc (PFE) by 45.87% based on its latest 2017Q3 regulatory filing with the SEC. Plancorp Llc sold 27,383 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 32,312 shares of the health care company at the end of 2017Q3, valued at $1.15M, down from 59,695 at the end of the previous reported quarter. Plancorp Llc who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $211.18 billion market cap company. The stock increased 0.68% or $0.239 during the last trading session, reaching $35.429. About 9.24 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since February 15, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Agf Investments Inc increased its stake in Synchrony Financial (SYF) by 7.66% based on its latest 2017Q3 regulatory filing with the SEC. Agf Investments Inc bought 59,783 shares as the company’s stock declined 26.83% while stock markets rallied. The institutional investor held 840,694 shares of the consumer services company at the end of 2017Q3, valued at $26.10M, up from 780,911 at the end of the previous reported quarter. Agf Investments Inc who had been investing in Synchrony Financial for a number of months, seems to be bullish on the $28.30B market cap company. The stock increased 0.10% or $0.03 during the last trading session, reaching $36.74. About 2.05 million shares traded. Synchrony Financial (NYSE:SYF) has declined 10.35% since February 15, 2017 and is downtrending. It has underperformed by 27.05% the S&P500.

Agf Investments Inc, which manages about $9.16 billion US Long portfolio, decreased its stake in Westrock Co. by 25,547 shares to 364,024 shares, valued at $20.65 million in 2017Q3, according to the filing. It also reduced its holding in Xilinx Inc. (NASDAQ:XLNX) by 64,046 shares in the quarter, leaving it with 127,223 shares, and cut its stake in Facebook Inc. (NASDAQ:FB).

Among 29 analysts covering Synchrony Financial (NYSE:SYF), 22 have Buy rating, 0 Sell and 7 Hold. Therefore 76% are positive. Synchrony Financial had 69 analyst reports since July 20, 2015 according to SRatingsIntel. On Monday, October 23 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. BMO Capital Markets maintained Synchrony Financial (NYSE:SYF) rating on Friday, October 6. BMO Capital Markets has “Buy” rating and $40.0 target. Susquehanna maintained Synchrony Financial (NYSE:SYF) rating on Thursday, December 28. Susquehanna has “Buy” rating and $47.0 target. The firm has “Buy” rating given on Wednesday, June 15 by Jefferies. The stock has “Buy” rating by BMO Capital Markets on Wednesday, August 23. The firm has “Perform” rating by Oppenheimer given on Tuesday, April 11. The stock of Synchrony Financial (NYSE:SYF) earned “Buy” rating by Nomura on Tuesday, October 20. As per Friday, October 20, the company rating was maintained by BMO Capital Markets. Susquehanna maintained the shares of SYF in report on Friday, January 19 with “Buy” rating. The firm has “Market Outperform” rating given on Monday, October 23 by JMP Securities.

Among 22 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pfizer had 74 analyst reports since July 29, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of PFE in report on Tuesday, November 21 with “Buy” rating. The company was downgraded on Thursday, October 13 by Jefferies. BMO Capital Markets maintained Pfizer Inc. (NYSE:PFE) on Monday, June 12 with “Hold” rating. The rating was maintained by Cowen & Co on Monday, July 10 with “Buy”. The rating was maintained by BMO Capital Markets with “Outperform” on Thursday, October 19. As per Wednesday, November 25, the company rating was upgraded by Suntrust Robinson. The stock of Pfizer Inc. (NYSE:PFE) has “Outperform” rating given on Monday, May 9 by Credit Suisse. Cowen & Co maintained Pfizer Inc. (NYSE:PFE) rating on Monday, August 14. Cowen & Co has “Buy” rating and $4300 target. On Wednesday, July 29 the stock rating was maintained by Argus Research with “Buy”. Societe Generale maintained the shares of PFE in report on Friday, March 24 with “Neutral” rating.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>